Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.58
SCR's Cash to Debt is ranked higher than
64% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. SCR: 1.58 )
SCR' s 10-Year Cash to Debt Range
Min: 0.22   Max: No Debt
Current: 1.58

Equity to Asset 0.61
SCR's Equity to Asset is ranked higher than
67% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. SCR: 0.61 )
SCR' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.85
Current: 0.61

0.31
0.85
Interest Coverage 0.57
SCR's Interest Coverage is ranked lower than
59% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.51 vs. SCR: 0.57 )
SCR' s 10-Year Interest Coverage Range
Min: 0.57   Max: 9999.99
Current: 0.57

0.57
9999.99
F-Score: 5
Z-Score: 2.64
M-Score: -2.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 1.90
SCR's Operating margin (%) is ranked higher than
58% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. SCR: 1.90 )
SCR' s 10-Year Operating margin (%) Range
Min: 1.9   Max: 20.5
Current: 1.9

1.9
20.5
Net-margin (%) 2.73
SCR's Net-margin (%) is ranked higher than
61% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. SCR: 2.73 )
SCR' s 10-Year Net-margin (%) Range
Min: 1.42   Max: 22.01
Current: 2.73

1.42
22.01
ROE (%) 2.83
SCR's ROE (%) is ranked higher than
61% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SCR: 2.83 )
SCR' s 10-Year ROE (%) Range
Min: 1.33   Max: 53.36
Current: 2.83

1.33
53.36
ROA (%) 1.69
SCR's ROA (%) is ranked higher than
63% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.95 vs. SCR: 1.69 )
SCR' s 10-Year ROA (%) Range
Min: 0.84   Max: 16.65
Current: 1.69

0.84
16.65
ROC (Joel Greenblatt) (%) 2.10
SCR's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.63 vs. SCR: 2.10 )
SCR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 2.1   Max: 84.99
Current: 2.1

2.1
84.99
Revenue Growth (%) 10.10
SCR's Revenue Growth (%) is ranked higher than
74% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SCR: 10.10 )
SCR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 23.3
Current: 10.1

0
23.3
EBITDA Growth (%) 2.10
SCR's EBITDA Growth (%) is ranked higher than
69% of the 504 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.00 vs. SCR: 2.10 )
SCR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 73
Current: 2.1

0
73
EPS Growth (%) 36.20
SCR's EPS Growth (%) is ranked higher than
91% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. SCR: 36.20 )
SCR' s 10-Year EPS Growth (%) Range
Min: -47.9   Max: 127.5
Current: 36.2

-47.9
127.5
» SCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SCR Guru Trades in Q1 2013

Murray Stahl 48,000 sh (unchged)
Jim Simons 25,600 sh (-51.42%)
» More
Q2 2013

SCR Guru Trades in Q2 2013

Jim Simons 27,800 sh (+8.59%)
Murray Stahl 48,000 sh (unchged)
» More
Q3 2013

SCR Guru Trades in Q3 2013

Jim Simons 39,600 sh (+42.45%)
Murray Stahl 48,000 sh (unchged)
» More
Q4 2013

SCR Guru Trades in Q4 2013

Jim Simons Sold Out
Murray Stahl Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SCR



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 7.60
SCR's P/E(ttm) is ranked higher than
98% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. SCR: 7.60 )
SCR' s 10-Year P/E(ttm) Range
Min: 7.02   Max: 190.17
Current: 7.6

7.02
190.17
P/B 1.27
SCR's P/B is ranked higher than
85% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. SCR: 1.27 )
SCR' s 10-Year P/B Range
Min: 0.92   Max: 4.28
Current: 1.27

0.92
4.28
P/S 1.54
SCR's P/S is ranked higher than
77% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. SCR: 1.54 )
SCR' s 10-Year P/S Range
Min: 1.11   Max: 5.19
Current: 1.54

1.11
5.19
Shiller P/E 16.15
SCR's Shiller P/E is ranked higher than
83% of the 363 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. SCR: 16.15 )
SCR' s 10-Year Shiller P/E Range
Min: 14.12   Max: 27.5
Current: 16.15

14.12
27.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 4.70
SCR's Price/Net Current Asset Value is ranked higher than
78% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. SCR: 4.70 )
SCR' s 10-Year Price/Net Current Asset Value Range
Min: 3.67   Max: 17.9
Current: 4.7

3.67
17.9
Price/Tangible Book 1.50
SCR's Price/Tangible Book is ranked higher than
83% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. SCR: 1.50 )
SCR' s 10-Year Price/Tangible Book Range
Min: 1.4   Max: 4.84
Current: 1.5

1.4
4.84
Price/DCF (Projected) 1.80
SCR's Price/DCF (Projected) is ranked higher than
68% of the 349 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. SCR: 1.80 )
SCR' s 10-Year Price/DCF (Projected) Range
Min: 1.75   Max: 4.12
Current: 1.8

1.75
4.12
Price/Median PS Value 0.90
SCR's Price/Median PS Value is ranked higher than
81% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. SCR: 0.90 )
SCR' s 10-Year Price/Median PS Value Range
Min: 0.74   Max: 2.78
Current: 0.9

0.74
2.78
Price/Graham Number 1.40
SCR's Price/Graham Number is ranked higher than
72% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. SCR: 1.40 )
SCR' s 10-Year Price/Graham Number Range
Min: 0.66   Max: 6.26
Current: 1.4

0.66
6.26
Earnings Yield (Greenblatt) 0.60
SCR's Earnings Yield (Greenblatt) is ranked lower than
67% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. SCR: 0.60 )
SCR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 24.8
Current: 0.6

0.6
24.8
Forward Rate of Return (Yacktman) -27.23
SCR's Forward Rate of Return (Yacktman) is ranked lower than
53% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. SCR: -27.23 )
SCR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -12.3   Max: 62.6
Current: -27.23

-12.3
62.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:VV5.Germany
Simcere Pharmaceutical Group was incorporated in the Cayman Islands as a listing vehicle on August 4, 2006. The Company is mainly engaged in the research, development, manufacture and distribution of pharmaceutical products in the People's Republic of China (the 'PRC'). The Company focuses its strategy on the development of first-to-market generic and innovative pharmaceuticals, and have introduced a first-to-market generic anti-stroke medication under the brand name Bicun, a 5-FU sustained release implant under the brand name Sinofuan, and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 45 main pharmaceutical products and the distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under the Company's brand names. As of March 31, 2009, the Company also had 12 product candidates in stages of development, including treatments for cancer, cerebrovascular diseases, infections, rheumatoid arthritis, nausea and vomiting associated with chemotherapy. The Company's main products are Antibacterial and Antiviral - Amoxicillin granules, capsules and tablets; Amoxicillin with clavulanate potassium granules, tablets and injection; biapenem injection; cefaclor dry suspension; azithromycin granules and ribavirin dispersible tablets; Anti-cancer - Recombinant human endostatin injection, nedaplatin injection, lentinan injection and fluorouracil implants. Anti-Allergic - Clemastine fumarate capsules and clemastine fumarate dry suspension; Anti-Osteoporosis - Alfacalcidol soft capsules Cardiovascular and Cerebrovascular - Edaravone injection; amlodipine maleate tablets and sumatriptan succinate tablets; Digestive Conditions - Smectite powder and aldioxa tablets; Non-Steroidal Anti-Inflammatory - Diclofenac sodium sustained-release capsules and gelatin; Respiratory System - Herbal medicine used for the treatment of cough in liquids and tablets; artificial cowbezoar and chlorphenamine maleate granules compound paracetamol and amantadine hydrochloride tablets; compound zinc gluconate; pediatric paracetamol; Urinary Conditions - Naftopidil tablets and herbal oral solutions. The main raw materials used for its products are the necessary active ingredients of its pharmaceuticals. The Company's source such raw materials, as well as packaging materials, from different independent suppliers in China. The Company's marketing and distribution activities are mainly carried out by its subsidiaries, Jiangsu Simcere and Shanghai Simcere. It sells all of the Company's products to pharmaceutical distributors in China. The Company relies mainly on a combination of patent, trademark and trade secret protections, as well as employee and third party confidentiality agreements to safeguard its intellectual property. The Company's operations and facilities are subject to environmental laws and regulations stipulated by the national and the local environment protect

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide